Mutations of the human BRCA2 gene confer susceptibility to breast cancer. A structural DNA binding component has been identified and is designated as BRCA2-Associated Factor 35 (BRAF35). There is a close association of the BRAF35/BRCA2 complex with condensed chromatin coincident with histone H3 phosphorylation. Experimental evidence suggests a role for the BRCA2/BRAF35 complex in the modulation of cell cycle progression.

Suitable for use in FLISA, Immunofluorescence, Western Blot and Immunohistochemistry. Other applications not tested.

Immunofluorescence: 10ug/ml Immunohistochemistry (Formalin fixed paraffin embedded): 1.8ug/ml Optimal dilutions to be determined by the researcher.

MLGAEWSKLQPTEKQRYLDEAEREKQQYMKELRAYQQSEAYKMCTEKIQEKKIKKEDSSSGLMNTLLNGHKGGDCDGFSTFDVPIFTEEFLDQNKAREAELRRLRKMNV

Store product at 4°C in the dark. DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: MaxLight™650 conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Note: Applications are based on unconjugated antibody.

Partial recombinant corresponding to aa1-109 from HMG20B (NP_006330) with GST tag. MW of the GST tag alone is 26kD.

Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with MaxLight™650.

Purified by Protein A affinity chromatography.

Recognizes human HMG20B.